How Morgan Stanley Currently Rates Perrigo (NYSE:PRGO)
Equity analysts at Morgan Stanley initiated coverage Perrigo (NYSE:PRGO) shares in recent note issued to clients on 3 December, IR.net reports. The financial firm has set a “Equal-Weight” rating on PRGO stock.
From a total of 13 analysts covering Perrigo Company Plc (NYSE:PRGO) stock, 9 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 60% of the ratings are positive. The highest target price is $237 while the lowest target price is $156. The mean of all analyst targets is $192.54 with a 34.94% above today’s ($146.18) stock price. Perrigo Company Plc was the topic of 8 analyst reports since October 23, 2015 according to the firm StockzIntelligence Inc. B. Riley & Co maintained shares on November 24 with “Buy” rating. UBS upgraded PRGO stock in a recent report from November 16 to “Buy” rating.
Approximately 322,273 shares of stock traded hands. Perrigo Company plc Ordinary Shares (NYSE:PRGO) has declined 19.33% since April 30, 2015 and is downtrending. It has underperformed by 19.04% the S&P500.
According to Zacks Investment Research, “Perrigo Company plc develops, manufactures and distributes healthcare products. The company operates primarily in four segments: Consumer Healthcare, Nutritionals, Rx Pharmaceutical and Active Pharmaceutical Ingredients. It also provides animal health products. The company operates primarily in the United States, the United Kingdom, Mexico, Israel, Australia, Canada, China and Latin America. Perrigo Company plc formerly known as Perrigo Company is headquartered in Ireland.” Get a free copy of the Zacks research report on Perrigo Company plc Ordinary Shares (PRGO).